NCT01626651View on ClinicalTrials.gov

A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Ibrutinib in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Healthy
Interventions
DRUG

Ibrutinib

A single oral dose of 120 mg ibrutinib (3 x 40 mg capsules) on Day 1, and 40 mg (1x 40 mg capsule) ibrutinib on Day 7.

DRUG

Ketoconazole

Ketoconazole (400 mg \[2 x 200 mg\] once daily) will be orally administered on Days 4, 5, 6, 7, 8 and 9.

Trial Locations (1)

Unknown

Neptune City

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT01626651 - A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Ibrutinib in Healthy Participants | Biotech Hunter | Biotech Hunter